Skip to main content
Erschienen in: World Journal of Surgery 7/2009

01.07.2009

Overexpression and Interactions of Interleukin-10, Transforming Growth Factor β, and Vascular Endothelial Growth Factor in Esophageal Squamous Cell Carcinoma

verfasst von: Mehran Gholamin, Omeed Moaven, Bahram Memar, Moein Farshchian, Hossein Naseh, Reza Malekzadeh, Masoud Sotoudeh, Mohammad Taghi Rajabi-Mashhadi, Mohammad Naser Forghani, Farid Farrokhi, Mohammad Reza Abbaszadegan

Erschienen in: World Journal of Surgery | Ausgabe 7/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

Sharing the role of immune suppression, interleukin-10 (IL-10), transforming growth factor β (TGF-β), and vascular endothelial growth factor (VEGF) are critical genes in several aspects of tumorigenesis. To elucidate the role of these cytokines in esophageal squamous cell carcinoma (ESCC), their relative mRNA expression in tumoral tissue compared with corresponding tumor-free tissue was evaluated.

Methods

A total of 49 patients with histologically confirmed ESCC were included in the study prior to any therapeutic interventions. Quantitative analysis of the mRNA expression was performed by real-time reverse transcription-polymerase chain reaction and the clinicopathologic associations were assessed.

Results

The mRNA of IL-10, VEGF, and TGF-β was frequently overexpressed in 53.2%, 44.9%, and 37.5% of ESCC patients, respectively. TGF-β was significantly co-expressed with IL-10 and with VEGF. Although VEGF was not independently associated with increased tumor size (p = 0.065), concomitant overexpression of VEGF with TGF-β was significantly correlated with increased size of the tumor (p < 0.05).

Conclusions

Overexpression of IL-10, TGF-β, and VEGF plays an important role in ESCC and consequently leads to the frequent event of immune evasion in ESCC. TGF-β is concomitantly overexpressed with IL-10 and with VEGF in ESCC. A stimulatory signal from TGF-β to VEGF is necessary for VEGF to promote tumor progression.
Literatur
1.
Zurück zum Zitat Sadjadi A, Nouraie M, Mohagheghi MA et al (2005) Cancer occurrence in Iran in 2002, an international perspective. Asian Pac J Cancer Prev 6:359–363PubMed Sadjadi A, Nouraie M, Mohagheghi MA et al (2005) Cancer occurrence in Iran in 2002, an international perspective. Asian Pac J Cancer Prev 6:359–363PubMed
2.
Zurück zum Zitat Yang L, Parkin DM, Li L et al (2003) Time trends in cancer mortality in China: 1987–1999. Int J Cancer 106:771–783PubMedCrossRef Yang L, Parkin DM, Li L et al (2003) Time trends in cancer mortality in China: 1987–1999. Int J Cancer 106:771–783PubMedCrossRef
3.
Zurück zum Zitat Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611PubMedCrossRef Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611PubMedCrossRef
4.
Zurück zum Zitat Bates DO, Curry FE (1996) Vascular endothelial growth factor increases hydraulic conductivity of isolated perfused microvessels. Am J Physiol 271:H2520–H2528PubMed Bates DO, Curry FE (1996) Vascular endothelial growth factor increases hydraulic conductivity of isolated perfused microvessels. Am J Physiol 271:H2520–H2528PubMed
5.
Zurück zum Zitat Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:579–591PubMedCrossRef Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:579–591PubMedCrossRef
6.
Zurück zum Zitat Huang CL, Liu D, Ishikawa S et al (2008) Wnt1 overexpression promotes tumour progression in non-small cell lung cancer. Eur J Cancer 44:2680–2688PubMedCrossRef Huang CL, Liu D, Ishikawa S et al (2008) Wnt1 overexpression promotes tumour progression in non-small cell lung cancer. Eur J Cancer 44:2680–2688PubMedCrossRef
7.
Zurück zum Zitat Furlan D, Sahnane N, Carnevali I et al (2008) Up-regulation of the hypoxia-inducible factor-1 transcriptional pathway in colorectal carcinomas. Hum Pathol 39:1483–1494PubMedCrossRef Furlan D, Sahnane N, Carnevali I et al (2008) Up-regulation of the hypoxia-inducible factor-1 transcriptional pathway in colorectal carcinomas. Hum Pathol 39:1483–1494PubMedCrossRef
8.
Zurück zum Zitat Oh SY, Kwon HC, Kim SH et al (2008) Clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer. BMC Cancer 8:123 Oh SY, Kwon HC, Kim SH et al (2008) Clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer. BMC Cancer 8:123
9.
Zurück zum Zitat Chen XY, Li JS, Liang QP et al (2008) Expression of PC cell-derived growth factor and vascular endothelial growth factor in esophageal squamous cell carcinoma and their clinicopathologic significance. Chin Med J (Engl) 121:881–886 Chen XY, Li JS, Liang QP et al (2008) Expression of PC cell-derived growth factor and vascular endothelial growth factor in esophageal squamous cell carcinoma and their clinicopathologic significance. Chin Med J (Engl) 121:881–886
10.
Zurück zum Zitat Moses HL, Yang EY, Pietenpol JA (1990) TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 63:245–247PubMedCrossRef Moses HL, Yang EY, Pietenpol JA (1990) TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 63:245–247PubMedCrossRef
11.
12.
Zurück zum Zitat Roberts AB, Sporn MB, Assoian RK et al (1986) Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83:4167–4171PubMedCrossRef Roberts AB, Sporn MB, Assoian RK et al (1986) Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83:4167–4171PubMedCrossRef
13.
Zurück zum Zitat Fontana A, Constam DB, Frei K et al (1992) Modulation of the immune response by transforming growth factor beta. Int Arch Allergy Immunol 99:1–7PubMedCrossRef Fontana A, Constam DB, Frei K et al (1992) Modulation of the immune response by transforming growth factor beta. Int Arch Allergy Immunol 99:1–7PubMedCrossRef
14.
Zurück zum Zitat Luwor RB, Kaye AH, Zhu JH (2008) Transforming growth factor-beta (TGF-β) and brain tumours. J Clin Neurosci 15:845–855PubMedCrossRef Luwor RB, Kaye AH, Zhu JH (2008) Transforming growth factor-beta (TGF-β) and brain tumours. J Clin Neurosci 15:845–855PubMedCrossRef
15.
Zurück zum Zitat Fukai Y, Fukuchi M, Masuda N et al (2003) Reduced expression of transforming growth factor-beta receptors is an unfavorable prognostic factor in human esophageal squamous cell carcinoma. Int J Cancer 104:161–166PubMedCrossRef Fukai Y, Fukuchi M, Masuda N et al (2003) Reduced expression of transforming growth factor-beta receptors is an unfavorable prognostic factor in human esophageal squamous cell carcinoma. Int J Cancer 104:161–166PubMedCrossRef
16.
Zurück zum Zitat Villanueva A, Garcia C, Paules AB et al (1998) Disruption of the antiproliferative TGF-β signaling pathways in human pancreatic cancer cells. Oncogene 17:1969–1978PubMedCrossRef Villanueva A, Garcia C, Paules AB et al (1998) Disruption of the antiproliferative TGF-β signaling pathways in human pancreatic cancer cells. Oncogene 17:1969–1978PubMedCrossRef
17.
Zurück zum Zitat Grady WM, Myeroff LL, Swinler SE et al (1999) Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancers. Cancer Res 59:320–324PubMed Grady WM, Myeroff LL, Swinler SE et al (1999) Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancers. Cancer Res 59:320–324PubMed
18.
Zurück zum Zitat Blobe GC, Schiemann WP, Lodish HF (2000) Role of transforming growth factor (beta) in human disease. N Engl J Med 343:228 Blobe GC, Schiemann WP, Lodish HF (2000) Role of transforming growth factor (beta) in human disease. N Engl J Med 343:228
19.
Zurück zum Zitat Volk H, Asadullah K, Gallagher G et al (2001) IL-10 and its homologs: important immune mediators and emerging immunotherapeutic targets. Trends Immunol 22:414–417PubMedCrossRef Volk H, Asadullah K, Gallagher G et al (2001) IL-10 and its homologs: important immune mediators and emerging immunotherapeutic targets. Trends Immunol 22:414–417PubMedCrossRef
20.
Zurück zum Zitat Wakkach A, Cottrez F, Groux H (2000) Can interleukin-10 be used as a true immunoregulatory cytokine? Eur Cytokine Netw 11:153–160PubMed Wakkach A, Cottrez F, Groux H (2000) Can interleukin-10 be used as a true immunoregulatory cytokine? Eur Cytokine Netw 11:153–160PubMed
21.
Zurück zum Zitat Kurte M, López M, Aguirre A et al (2004) A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and transporter associated with antigen processing 1/2 in human melanoma cells. J Immunol 173:1731–1737PubMed Kurte M, López M, Aguirre A et al (2004) A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and transporter associated with antigen processing 1/2 in human melanoma cells. J Immunol 173:1731–1737PubMed
22.
Zurück zum Zitat Kundu N, Dorsey R, Jackson MJ et al (1998) Interleukin-10 gene transfer inhibits murine mammary tumors and elevates nitric oxide. Int J Cancer 76:713–719PubMedCrossRef Kundu N, Dorsey R, Jackson MJ et al (1998) Interleukin-10 gene transfer inhibits murine mammary tumors and elevates nitric oxide. Int J Cancer 76:713–719PubMedCrossRef
23.
Zurück zum Zitat Kohno T, Mizukami H, Suzuki M et al (2003) Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. Cancer Res 63:5091–5094PubMed Kohno T, Mizukami H, Suzuki M et al (2003) Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. Cancer Res 63:5091–5094PubMed
24.
Zurück zum Zitat Asadullah K, Sterry W, Volk HD (2003) Interleukin-10 therapy: review of a new approach. Pharmacol Rev 55:241–269PubMedCrossRef Asadullah K, Sterry W, Volk HD (2003) Interleukin-10 therapy: review of a new approach. Pharmacol Rev 55:241–269PubMedCrossRef
25.
Zurück zum Zitat Koliopanos A, Friess H, di Mola FF et al (2002) Connective tissue growth factor gene expression alters tumor progression in esophageal cancer. World J Surg 26:420–427PubMedCrossRef Koliopanos A, Friess H, di Mola FF et al (2002) Connective tissue growth factor gene expression alters tumor progression in esophageal cancer. World J Surg 26:420–427PubMedCrossRef
26.
Zurück zum Zitat Oka M, Hirose K, Iizuka N et al (1995) Cytokine mRNA expression patterns in human esophageal cancer cell lines. J Interferon Cytokine Res 15:1005–1009PubMedCrossRef Oka M, Hirose K, Iizuka N et al (1995) Cytokine mRNA expression patterns in human esophageal cancer cell lines. J Interferon Cytokine Res 15:1005–1009PubMedCrossRef
27.
Zurück zum Zitat Loges S, Clausen H, Reichelt U et al (2007) Determination of microvessel density by quantitative real-time PCR in esophageal cancer: correlation with histologic methods, angiogenic growth factor expression, and lymph node metastasis. Clin Cancer Res 13:76–80PubMedCrossRef Loges S, Clausen H, Reichelt U et al (2007) Determination of microvessel density by quantitative real-time PCR in esophageal cancer: correlation with histologic methods, angiogenic growth factor expression, and lymph node metastasis. Clin Cancer Res 13:76–80PubMedCrossRef
28.
Zurück zum Zitat Kapral M, Strzalka B, Kowalczyk M et al (2008) Transforming growth factor beta isoforms (TGF-beta1, TGF-beta2, TGF-beta3) messenger RNA expression in laryngeal cancer. Am J Otolaryngol 29:233–237PubMedCrossRef Kapral M, Strzalka B, Kowalczyk M et al (2008) Transforming growth factor beta isoforms (TGF-beta1, TGF-beta2, TGF-beta3) messenger RNA expression in laryngeal cancer. Am J Otolaryngol 29:233–237PubMedCrossRef
29.
Zurück zum Zitat Diaz-Chavez J, Hernandez-Pando R, Lambert PF et al (2008) Down-regulation of transforming growth factor-beta type II receptor (TGF-betaRII) protein and mRNA expression in cervical cancer. Mol Cancer 7:3PubMedCrossRef Diaz-Chavez J, Hernandez-Pando R, Lambert PF et al (2008) Down-regulation of transforming growth factor-beta type II receptor (TGF-betaRII) protein and mRNA expression in cervical cancer. Mol Cancer 7:3PubMedCrossRef
30.
Zurück zum Zitat Abe H, Yamanishi T, Mashidori T et al (2008) Significant association of interleukin 10 receptor mRNA levels with renal cell carcinoma metastasis. Biomed Res 29:19–25PubMedCrossRef Abe H, Yamanishi T, Mashidori T et al (2008) Significant association of interleukin 10 receptor mRNA levels with renal cell carcinoma metastasis. Biomed Res 29:19–25PubMedCrossRef
31.
Zurück zum Zitat Ohm JE, Gabrilovich DI, Sempowski GD et al (2003) VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101:4878–4886PubMedCrossRef Ohm JE, Gabrilovich DI, Sempowski GD et al (2003) VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101:4878–4886PubMedCrossRef
32.
Zurück zum Zitat Yang WF, Yu JM, Zuo WS et al (2006) Expression of CD80, CD86, TGF-beta1 and IL-10 mRNA in the esophageal carcinoma. Zhonghua Zhong Liu Za Zhi 28:762–765PubMed Yang WF, Yu JM, Zuo WS et al (2006) Expression of CD80, CD86, TGF-beta1 and IL-10 mRNA in the esophageal carcinoma. Zhonghua Zhong Liu Za Zhi 28:762–765PubMed
33.
Zurück zum Zitat Kaklamani VG, Pasche B (2004) Role of TGF-beta in cancer and the potential for therapy and prevention. Expert Rev Anticancer Ther 4:649–661PubMedCrossRef Kaklamani VG, Pasche B (2004) Role of TGF-beta in cancer and the potential for therapy and prevention. Expert Rev Anticancer Ther 4:649–661PubMedCrossRef
34.
Zurück zum Zitat Loskog A, Dzojic H, Vikman S et al (2004) Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor microenvironment. J Immunol 172:7200–7205PubMed Loskog A, Dzojic H, Vikman S et al (2004) Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor microenvironment. J Immunol 172:7200–7205PubMed
35.
Zurück zum Zitat Nagata J, Kijima H, Hatanaka H et al (2002) Correlation between interleukin 10 and vascular endothelial growth factor expression in human esophageal cancer. Int J Mol Med 10:169–172PubMed Nagata J, Kijima H, Hatanaka H et al (2002) Correlation between interleukin 10 and vascular endothelial growth factor expression in human esophageal cancer. Int J Mol Med 10:169–172PubMed
36.
Zurück zum Zitat Merogi AJ, Marrogi AJ, Ramesh R et al (1997) Tumor–host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas. Hum Pathol 28:321–331PubMedCrossRef Merogi AJ, Marrogi AJ, Ramesh R et al (1997) Tumor–host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas. Hum Pathol 28:321–331PubMedCrossRef
37.
Zurück zum Zitat D’Orazio TJ, Niederkorn JY (1998) A novel role for TGF-beta and IL-10 in the induction of immune privilege. J Immunol 160:2089–2098PubMed D’Orazio TJ, Niederkorn JY (1998) A novel role for TGF-beta and IL-10 in the induction of immune privilege. J Immunol 160:2089–2098PubMed
38.
Zurück zum Zitat Li D, Zhang C, Song F et al (2009) VEGF regulates FGF-2 and TGF-beta1 expression in injury endothelial cells and mediates smooth muscle cells proliferation and migration. Microvasc Res 77:134–142PubMedCrossRef Li D, Zhang C, Song F et al (2009) VEGF regulates FGF-2 and TGF-beta1 expression in injury endothelial cells and mediates smooth muscle cells proliferation and migration. Microvasc Res 77:134–142PubMedCrossRef
39.
Zurück zum Zitat Wang XJ, Dong Z, Zhong XH et al (2008) Transforming growth factor-beta1 enhanced vascular endothelial growth factor synthesis in mesenchymal stem cells. Biochem Biophys Res Commun 365:548–554PubMedCrossRef Wang XJ, Dong Z, Zhong XH et al (2008) Transforming growth factor-beta1 enhanced vascular endothelial growth factor synthesis in mesenchymal stem cells. Biochem Biophys Res Commun 365:548–554PubMedCrossRef
40.
Zurück zum Zitat Boström K, Zebboudj AF, Yao Y et al (2004) Matrix GLA protein stimulates VEGF expression through increased transforming growth factor-beta1 activity in endothelial cells. J Biol Chem 279:52904–52913PubMedCrossRef Boström K, Zebboudj AF, Yao Y et al (2004) Matrix GLA protein stimulates VEGF expression through increased transforming growth factor-beta1 activity in endothelial cells. J Biol Chem 279:52904–52913PubMedCrossRef
41.
Zurück zum Zitat Benckert C, Jonas S, Cramer T et al (2003) Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 63:1083–1092PubMed Benckert C, Jonas S, Cramer T et al (2003) Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 63:1083–1092PubMed
42.
Zurück zum Zitat Ferrari G, Pintucci G, Seghezzi G et al (2006) VEGF, a prosurvival factor, acts in concert with TGF-beta1 to induce endothelial cell apoptosis. Proc Natl Acad Sci USA 103:17260–17265PubMedCrossRef Ferrari G, Pintucci G, Seghezzi G et al (2006) VEGF, a prosurvival factor, acts in concert with TGF-beta1 to induce endothelial cell apoptosis. Proc Natl Acad Sci USA 103:17260–17265PubMedCrossRef
Metadaten
Titel
Overexpression and Interactions of Interleukin-10, Transforming Growth Factor β, and Vascular Endothelial Growth Factor in Esophageal Squamous Cell Carcinoma
verfasst von
Mehran Gholamin
Omeed Moaven
Bahram Memar
Moein Farshchian
Hossein Naseh
Reza Malekzadeh
Masoud Sotoudeh
Mohammad Taghi Rajabi-Mashhadi
Mohammad Naser Forghani
Farid Farrokhi
Mohammad Reza Abbaszadegan
Publikationsdatum
01.07.2009
Verlag
Springer-Verlag
Erschienen in
World Journal of Surgery / Ausgabe 7/2009
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-009-0070-y

Weitere Artikel der Ausgabe 7/2009

World Journal of Surgery 7/2009 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.